Greater average vision gains observed with EYLEA® vs. ranibizumab in Year 11,a

A Cochrane network meta-analysis demonstrated that:1,b

  • DME patients are 30% more likely to gain ≥3-lines with EYLEA vs. ranibizumab in Year 1
  • All efficacy outcomes significantly favoured EYLEA over ranibizumab in Year 1
Cochrane Analysis: Mean change in VA over time (aflibercept, ranibizumab, bevacizumab)

“The difference between aflibercept and ranibizumab was consistent with indirect evidence based on studies that mostly used ranibizumab 0.5 mg, suggesting no dose effect”1,a

a This Cochrane meta-analysis included data from Protocol T where the dose of ranibizumab tested was 0.3 mg (US-approved dosage), while the ex-US dosage of ranibizumab is 0.5 mg. The treatment regimen tested in Protocol T was not the label regimen for either EYLEA or ranibizumab.
b Meta-analysis using Cochrane methods (based on a search of databases conducted in April 2017) of RCTs with anti-VEGF agents in DME patients, focused on the three most commonly used drugs: EYLEA, ranibizumab and unlicensed bevacizumab. The analysis included 24 studies and 6007 eyes in total. 17 studies (4031 eyes) were assessed for VA data.
c Bevacizumab is not licensed for the treatment of DME.

DME, diabetic macular edema; RCT, randomized controlled trial; VA, visual acuity; VEGF, vascular endothelial growth factor.

Reference

  1. Virgili G, Parravano M, Evans JR, et al. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2017;6:CD007419.